Affinivax

Biotech & Life Sciences · Cambridge, United States · Founded 2014

Affinivax is a clinical-stage biotechnology company specializing in the development of next-generation vaccines and immunotherapies. The company operates in the healthcare and biotechnology market, focusing on infectious and immune-mediated diseases. Affinivax's core technology, the Multiple Antigen Presenting System (MAPS), enables the high-affinity binding of polysaccharides and proteins in a single vaccine. This unique approach induces a broad and protective B and T cell immune response, offering novel preventive and therapeutic solutions. The company's lead vaccine program targets Streptococcus pneumoniae, a significant cause of pneumonia and other serious infections. Affinivax generates revenue through partnerships, grants, and potential future sales of its proprietary vaccines. The company serves healthcare providers, patients, and global health organizations. Keywords: MAPS technology, vaccines, immunotherapies, Streptococcus pneumoniae, biotechnology, immune response, polysaccharides, proteins, healthcare, clinical-stage.

Valuation $1–2.5B

Headcount <100

Total funding $100–500M

Unlock exact values

Power Law Unicorn$1–10B valuation tier

Investors

14 investors on Affinivax's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage

Bill & Melinda Gates Foundation

Series A 2 investors entered at this stage

Viking Global Investors

Bain Capital Life Sciences

Series B+ 11 investors entered at this stage

Foresite Capital

Rock Springs Capital

EcoR1 Capital

Ziff Capital Partners

BlackRock

Citadel

Cormorant Asset Management

Wellington Management

Perceptive Advisors

T. Rowe Price

Logos Capital

Global footprint

Where Affinivax has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Talent graph

The shape of Affinivax's talent

Dealroom maps Affinivax's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

8 team members profilednamed & role-tagged by Dealroom

10 employeestotal headcount

3 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Affinivax's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$11M patent portfolio · 7 active families

Estimated portfolio value

$11M

0.53% of valuation · 2.2× smaller than top peer Liquidia Technologies ($25M)

7 active patent families

Where Affinivax innovates Biomedical engineeringCoronavirusCoronavirus vaccinationImmunogenicityMechanical engineering

Where Affinivax concentrates vs peers

Each axis is a top-10 topic across Affinivax and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Affinivax

An AI-synthesized read of the highest-engagement posts about Affinivax on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Affinivax on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles